Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
3(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
4%
Ph phase_4
7
30%
Ph not_applicable
4
17%
Ph phase_2
2
9%
Ph phase_3
6
26%
Ph phase_1
3
13%

Phase Distribution

4

Early Stage

2

Mid Stage

13

Late Stage

Phase Distribution23 total trials
Early Phase 1First-in-human
1(4.3%)
Phase 1Safety & dosage
3(13.0%)
Phase 2Efficacy & side effects
2(8.7%)
Phase 3Large-scale testing
6(26.1%)
Phase 4Post-market surveillance
7(30.4%)
N/ANon-phased studies
4(17.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

23

all time

Status Distribution
Active(7)
Completed(13)
Other(3)

Detailed Status

Completed13
unknown3
Enrolling by invitation3
Recruiting2
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.3%)
Phase 13 (13.0%)
Phase 22 (8.7%)
Phase 36 (26.1%)
Phase 47 (30.4%)
N/A4 (17.4%)

Trials by Status

active_not_recruiting14%
completed1357%
recruiting29%
not_yet_recruiting14%
unknown313%
enrolling_by_invitation313%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT06955520Not Applicable

Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM

Recruiting
NCT06953986Not Applicable

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks

Recruiting
NCT06523764Phase 4

Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment

Active Not Recruiting
NCT06811207Phase 3

Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication

Enrolling By Invitation
NCT06509139Phase 4

Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males

Enrolling By Invitation
NCT05443984Phase 3

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Completed
NCT04527055Phase 4

The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication

Enrolling By Invitation
NCT06318104Phase 4

Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole

Not Yet Recruiting
NCT05841394Phase 3

A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding

Completed
NCT04282954Phase 2

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

Completed
NCT05100446Early Phase 1

Comparison Between High-dose Amoxicillin Dual Therapy and Pylera Quadruple Therapy in the Treatment of Helicobacter Pylori Infection

Unknown
NCT03980756Phase 1

A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole

Completed
NCT03736369Phase 3

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

Completed
NCT03615677Phase 3

Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis

Completed
NCT04329000Not Applicable

On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.

Completed
NCT04090021Phase 4

Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.

Unknown
NCT03598738Not Applicable

The Effect of Esomeprazole on Type 2 Diabetes

Completed
NCT03555526Phase 4

Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection

Unknown
NCT03006874Phase 3

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Completed
NCT01538849Phase 2

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23